Welcome to our dedicated page for Alterity Therapeutics American Depositary Shares news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics American Depositary Shares stock.
Alterity Therapeutics Limited (symbol: ATHE) is a pioneering biopharmaceutical company based in Melbourne, Australia, focused on developing therapeutic drugs for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple system atrophy. Founded in 1997 and originally known as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics Limited in April 2019.
The company’s flagship drug candidate, ATH434, has successfully completed Phase I clinical trials and is geared towards treating Parkinson's disease and other associated movement disorders. The drug has shown promise in clinical evaluations to slow disease progression, thus improving the quality of life for patients.
Alterity is also advancing PBT2, another leading drug candidate, originally designed as an antimicrobial agent but repurposed for treating Alzheimer's and Huntington's diseases. PBT2 has garnered attention owing to its potential to tackle the cognitive decline associated with these debilitating conditions.
Alterity Therapeutics is actively engaged in multiple research collaborations and partnerships with academic institutions and pharmaceutical companies to enhance its drug development pipeline. Their multi-faceted approach to addressing neurodegenerative disorders underscores the company's commitment to innovation and patient care.
Recent achievements include a collaborative study titled “A multimodal approach for diagnosis of early Multiple System Atrophy,” presented at the MDS 2023 conference, demonstrating the company's dedication to advancing scientific understanding and treatment methodologies.
Financially, Alterity Therapeutics maintains a stable condition, actively investing in research and development to push forward its clinical programs. The company's strategic initiatives and ongoing projects highlight its pivotal role in the healthcare domain, with a focus on creating significant therapeutic advancements.
For investors and stakeholders, Alterity Therapeutics represents a compelling opportunity in the biopharmaceutical sector, with a clear focus on addressing unmet medical needs through innovative drug discovery and development.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced the opening of enrollment for its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) in the UK. This trial aims to assess the treatment's impact on neuroimaging and protein biomarkers, targeting around 60 adult patients. ATH434 has shown promise in preclinical studies, demonstrating the ability to inhibit pathogenic protein aggregation and restore normal iron balance in the brain. MSA affects approximately 15,000 individuals in the U.S., with no current market-approved drugs to slow its progression.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has commenced its Phase 2 clinical trial for ATH434 in New Zealand, focusing on Multiple System Atrophy (MSA), a rare Parkinsonian disorder. The regulatory bodies in the U.K. and Italy have granted approval for this trial. The company reported a cash balance of A$34.8 million as of June 30, 2022, with cash outflows of A$4.4 million. Additionally, it received A$4.1 million from the R&D Tax Incentive Scheme, supporting its research and development efforts.
Alterity Therapeutics has announced the dosing of the first patient in its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA), a severe neurodegenerative disease. This trial, which aims to enroll approximately 60 adult patients, is designed to evaluate the safety and efficacy of ATH434 over 12 months. MSA affects about 15,000 individuals in the U.S., and current treatments fail to slow its progression. ATH434 has shown promise in preclinical studies and is the first small molecule designed to target the pathological proteins involved in MSA.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received authorization from the Italian Medicines Agency to conduct a Phase 2 clinical trial for ATH434 targeting Multiple System Atrophy (MSA), a severe Parkinsonian disorder. The trial aims to enroll approximately 60 patients, assessing ATH434's impact on biomarkers and clinical endpoints over 12 months. This approval affirms the company’s strategy to reach a global patient base affected by MSA, with ongoing efforts to open study sites in New Zealand, the UK, and Italy. ATH434, previously successful in Phase 1 trials, has Orphan designation for MSA treatment.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that its Phase 2 clinical trial for ATH434, aimed at treating Multiple System Atrophy (MSA), is now open for enrollment in New Zealand. MSA is a rare neurodegenerative disease characterized by rapid progression and severe disability. ATH434 is intended to reduce α-synuclein accumulation and restore iron balance in the brain, addressing the disease's underlying pathology. The trial will include approximately 60 patients, assessing efficacy and safety over a 12-month treatment period.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received approval from the UK's Medicines & Healthcare products Regulatory Agency (MHRA) for its Phase 2 clinical trial of ATH434, aimed at treating Multiple System Atrophy (MSA), a debilitating neurodegenerative condition. The trial will begin in New Zealand and expand to other regions, including the UK and the U.S. ATH434 targets protein aggregation and aims to improve patient outcomes. This follows a successful Phase 1 trial, highlighting ATH434's potential as a novel treatment for patients with no current options.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced new data from its ongoing bioMUSE study at the AAN Annual Meeting on April 6, 2022. This natural history study tracks disease progression in early Multiple System Atrophy (MSA) patients. It highlights a correlation between iron accumulation in the brain and disease severity, reinforcing the potential of quantitative susceptibility mapping as a biomarker. The study included data from 52 individuals and supports the upcoming global Phase 2 trial of ATH434, aimed at treating MSA by reducing iron accumulation and inhibiting protein aggregation.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on treatments for neurodegenerative diseases, announced that CEO David Stamler will present at the 34th Annual Roth Conference on March 14-15, 2022, in Dana Point, California. The company's lead asset, ATH434, targets Parkinsonian disorders, while its drug discovery platform aims to develop innovative treatments. A recorded presentation is available on the Alterity website.
Alterity Therapeutics (ATHE) has announced the publication of research demonstrating that its drug candidate, ATH434, shows promise in treating Multiple System Atrophy (MSA). Published in the Journal of Parkinson's Disease, the study revealed that ATH434 reduced toxic forms of α-synuclein in a murine model, preserved neurons, and improved motor performance. The research led by Dr. David Finkelstein highlighted ATH434's potential for clinical application, with ongoing Phase 2 trials planned. The compound has received Orphan Drug designation from the FDA and the European Commission.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has received authorization from New Zealand's Medsafe for a Phase 2 clinical trial of its lead drug candidate ATH434, targeting Multiple System Atrophy (MSA). The trial aims to assess ATH434's impact on imaging and biomarkers over 12 months. The company reported a cash position of A$37M as of December 31, 2021, with operating cash outflows of A$4M. Additionally, a recent US patent grants exclusivity for a new class of iron chaperones, potentially beneficial for treating Parkinson's and Alzheimer's diseases.
FAQ
What is the current stock price of Alterity Therapeutics American Depositary Shares (ATHE)?
What is the market cap of Alterity Therapeutics American Depositary Shares (ATHE)?
What does Alterity Therapeutics Limited specialize in?
What are the company's lead drug candidates?
Where is Alterity Therapeutics Limited based?
What was Alterity Therapeutics formerly known as?
What recent achievements has the company made?
Who is the CEO of Alterity Therapeutics Limited?
What is the financial condition of Alterity Therapeutics?
What does ATH434 target?
What does PBT2 target?
What type of collaborations is Alterity Therapeutics engaged in?
